J&J sues Amgen over cancer drug sales tactics

10/14/2005 | NYTimes.com

Johnson & Johnson filed an antitrust suit alleging Amgen used sales tactics to force cancer clinics to buy its Aranesp rather than J&J's Procrit, drugs used to treat chemotherapy-related anemia. The suit notes U.S. sales of the two drugs are expected to reach $2.8 billion this year. An Amgen spokeswoman said, "We believe the allegations are not legitimate and we intend to fight this."

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA